You are here

Stored NovoLog Can Remain in Pump Reservoir for up to Six Days

PRINCETON, N.J., July 15 /PRNewswire-FirstCall/ -- Diabetes patients taking NovoLog (insulin aspart [rDNA origin] injection) can now use the insulin in their pump for up to six days following the U.S. Food and Drug Administration (FDA) approval of a labeling change, diabetes care company Novo Nordisk announced today. The previous label allowed for NovoLog to be stored in the pump reservoir for two days. This makes NovoLog the first and only rapid-acting insulin with this extended in-use time.

An insulin pump is a small, battery powered device designed to constantly deliver insulin into the patient's body 24 hours a day according to a preset program. Approximately the size of a pager, the pump system is composed of a reservoir for the insulin, a small battery, the pump, and a thin plastic tube with a needle on the end that passes insulin into the body, called the infusion set.

The updated NovoLog label also states that patients using NovoLog in their pumps should change the infusion set and the infusion set insertion site at least every three days. The previous label stated that NovoLog in the pump reservoir, infusion set and the infusion set insertion site be changed at least every 48 hours. The revised label keeps the same recommendation that NovoLog should be discarded after exposure to temperatures that exceed 37 degrees C (98.6 degrees F).

"The ability to go longer between changes of insulin in the pump allows people with diabetes to have more active and flexible lifestyles, which are integral to the success of long-term diabetes management," said Richard R. Rubin, PhD, professor, medicine and pediatrics, The Johns Hopkins University School of Medicine.

The label change is based on the FDA's review of data from Novo Nordisk that showed the stability of NovoLog in the pump for up to six days.

NovoLog is a rapid-acting insulin analog, meaning it works faster and for a shorter period of time compared with regular human insulin. NovoLog is also available in FlexPen , the world's #1 selling prefilled insulin pen. Diabetes patients who take NovoLog can eat within 5-10 minutes of use, rather than the typical 30 minutes required with regular human insulin.

NovoLog was first approved by the FDA in 2000 and approved for use in pumps in 2001.

Source: Novo Nordisk

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids